By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Novartis Corporation 

608 5th Avenue

New York  New York  10020  U.S.A.
Phone: 212-307-1122 Fax: 212-246-0185



Medarex, Inc.  Broad HuMAb-Mouse antibody development agreement.

Celgene (San Diego)  Discovery and Development of Selective estrogen receptor modulators for the treatment of osteoporosis

Celgene (San Diego)  Commercialization of FocalinTM for ADHD


Entelos, Inc. 

Human Genome Sciences, Inc. 

Peptimmune, Inc.  Exclusive option to obtain exclusive worldwide rights to develop and commercialize PI-2301, Peptimmune‚Äôs multiple sclerosis drug candidate.


Company News
Novartis Corporation (NVS) Breakthrough Therapy LDK378 Shows a Marked Clinical Response in Patients With ALK+ Non-Small Cell Lung Cancer 6/3/2013 11:47:29 AM
Novartis Corporation (NVS) Release: 8 Scottish Life Science Companies Descend Upon Boston in Search of Investors and Partners 6/15/2012 9:57:10 AM
Novartis Corporation (NVS) Sits in the Penalty Box 4/25/2012 8:07:17 AM
FDA Approves Novartis Corporation (NVS)'s Gleevec for Expanded Use in Patients With Rare Gastrointestinal Cancer 2/1/2012 6:44:03 AM
Endo Pharmaceuticals (ENDP) Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Corporation (NVS)Facility 1/9/2012 11:51:10 AM
Novartis Corporation (NVS) Pivotal Study of Exjade(R) Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia 12/13/2011 11:39:43 AM
Novartis Corporation (NVS) Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 11/7/2011 11:40:52 AM
Viamet Pharmaceuticals Appoints Former Novartis Corporation (NVS) Executive Marc Rudoltz, M.D. as Chief Medical Officer 11/3/2011 9:17:37 AM
Novartis Corporation (NVS) Release: IBM Corporation (IBM) Launches University Competition to Combat Growth of Non-Communicable Diseases 10/10/2011 6:01:01 AM
Novartis AG (NVS) Receives Approval in Japan for Two Innovative Therapies, Gilenya(R) in MS and Ilaris(R) in CAPS 9/27/2011 7:43:31 AM